Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2004, 50, 184-193

https://doi.org/10.14712/fb2004050060184

Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects

Marie Indrová1, M. Reiniš1, J. Bubeník1, T. Jandlová1, J. Bieblová1, V. Vonka2, J. Velek3

1Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
2Institute of Haematology and Blood Transfusion, Prague, Czech Republic
3Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received October 2004
Accepted November 2004

We have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. Dendritic cells loaded with the HPV16 E6/E7 peptides exhibiting CTL or Th epitopes (E641-50, E681-90, E698-107, E6130-137, E749-57, and E744-62) were able to stimulate in vitro DNA synthesis in syngeneic H-2b spleen cells. The priming capacity of peptide-loaded BMDC and peptide-loaded dendritic cell lines DC2.4 and JAWS II was compared. It has been found that both peptide-loaded BMDC and established dendritic cell lines can activate the syngeneic responder cells, but the priming capacity of BMDC was substantially higher. In the second set of experiments, we have examined the cytolytic activity of syngeneic spleen cells after repeated activation in vitro with BMDC loaded with HPV16 synthetic peptides containing CTL epitopes. Significant cytotoxic responses against HPV16 E6/E7 antigen-expressing TC-1 targets have been found after repeated in vitro activation with all peptides containing the CTL epitopes. In contrast, peptide E744-62 harbouring both Th and CTL epitopes induced significant cytotoxic responses already after single in vitro activation. This cytotoxic effect could be enhanced with admixture of the E749-57 peptide. Experiments with MHC class I proficient (TC-1, MK16-IFNγ) and deficient (MK16) target cells revealed that the dendritic cells loaded with the E6/E7 HPV16 peptides activated CTLs in vitro, but not the other cytolytic effector mechanisms. The effectiveness of the peptide-loaded BMDC-based cellular vaccines was also investigated in vivo. C57BL/6 (H-2b) mice were immunized with various peptide-loaded BMDC and subsequently challenged with TC-1 cells. The strongest protective effect was achieved with the BMDC loaded with the peptide E744-62 harbouring both CTL and Th epitopes. Mice immunized with the E744-62 peptide remained tumour-free after s.c. transplantation of the TC-1 cells and exhibited long-lasting protective immunity, whereas the mice immunized with E681-90 and E749-57 peptides did not remain tumour-free and exhibited only partial inhibition of tumour growth detectable as depression of the tumour growth curves.

Funding

This project was supported by NIH Research Grant # D43 TW000233 funded by the Fogarty International Center, the National Institute on Drug Abuse and the National Heart Lung and Blood Institute, by grants Nos. NC 7148-3 and NR 7807-3 from the Grant Agency of the Ministry of Health of the Czech Republic, Nos. 301/01/0985 and 301/04/0492 from the Grant Agency of the Czech Republic; by the project No. K5011112 awarded by the Academy of Sciences of the Czech Republic, and by the League against Cancer, Prague.

References

26 live references